The Current Role of Plasma-Derived Therapies for Hemophilia A
November 26, 2019
November 26, 2020
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Postgraduate Institute for Medicine (PIM) and CMEology.
Supported by an educational grant from Kedrion Biopharma Inc.
- Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)™
- Nurses — 0.5 Contact hour
All other health care professionals completing this course will be issued a statement of participation.
This accredited activity is designed to address the educational needs of specialists who care for patients with hemophilia A.
Upon completion of this activity, participants should be able to:
- Summarize best practices in controversial aspects of hemophilia A care
- Identify the current, evolving, and future roles for plasma-derived FVIII
Robert Sidonio, Jr., MD
Assistant Professor of Pediatrics and Director of Clinical Operations
Hemostasis and Thrombosis Program
Emory University School of Medicine
Aflac Cancer and Blood Disorders Center
at Children’s Healthcare of Atlanta
Guy Young, MD
Director of the Hemostasis and Thrombosis Center
Children’s Hospital Los Angeles
Professor of Pediatrics
University of Southern California Keck School of Medicine
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and CMEology. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour.
Disclosures of Conflicts of Interest
Robert Sidonio, Jr., MD
- Consultant/Advisor: Aptevo, Bayer, BioMarin, Genentech, Novo Nordisk, Octapharma, Sanofi, Takeda, and UniQure
- Fees for Non-CME/CE Services Received Directly from a Commercial Interest (eg, speakers’ bureaus): Sanofi
- Research Support: Genentech, Kedrion/Grifols, Octapharma, Sanofi, and Takeda
Guy Young, MD
- Consultant/Advisor: CSL Behring, Genentech, Takeda, and UniQure
- Fees for Non-CME/CE Services Received Directly from a Commercial Interest (eg, speakers’ bureaus): Genentech, Grifols, Roche, and Spark
- Research Support: Genentech
CMEology planners have no relationships to disclose.
PIM content reviewers have no relationships to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Instructions for Participation and Credit
During the period March 9, 2020 through November 26, 2020, participants must: 1) read the learning objectives and disclosures; 2) study the educational activity; 3) complete the post-test with a score of 75% or better with no more than 3 attempts; and 4) complete the activity evaluation. Once you complete the online evaluation, your certificate will be made available immediately. Click on View Certificate and print the certificate for your records.
Hardware and Software Requirements
This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser.
Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
The opinions expressed in this educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.